Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 9/20 | 0.47 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25452983 | 0.87 | PDE2A (0.35) | PDE2AKIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL1694994 | 0.86 | ALDH1A1 (0.43) | PDE2AKIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL7601744 | 0.84 | CES2 (0.52) | PDE2AKIF11CES2IDO1MPL | |
| SCHEMBL4792748 | 0.83 | KIF11 (0.46) | PDE2AKIF11 | |
| SCHEMBL9967853 | 0.83 | KIF11 (0.44) | PDE2AKIF11CES2IDO1APP | |
| SCHEMBL19170782 | 0.82 | KIF11 (0.47) | PDE2AKIF11CES2 | |
| SCHEMBL13130675 | 0.81 | ALDH1A1 (0.34) | PDE2AKIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL24836121 | 0.80 | PDE2A (0.47) | PDE2AKIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL11999123 | 0.80 | PDE2A (0.58) | PDE2AKIF11CES2 | |
| SCHEMBL8220447 | 0.80 | PDE2A (0.49) | PDE2AKIF11CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912822-B2 | Process of manufacturing polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912822-B2 | Process of manufacturing polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230312803-A1 | POLYURETHANE COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230312803-A1 | POLYURETHANE COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100010093-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-7608604-B2 | Antiparasitic agents | PFIZER LIMITED (GB) | 2009-10-27 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | PFIZER LIMITED (UK) | 2008-08-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | PDE2A 3948/4885KIF11 3410/4885HDAC3 497/4885 |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | HRH4, HRH3, HRH2 | PDE2A 3598/4885KIF11 2214/4885HDAC3 37/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | PDE2A 1337/4885KIF11 2802/4885HDAC3 1216/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PDE2A 2430/4885KIF11 4469/4885HDAC3 22/4885 |
| US-11912822-B2 | Process of manufacturing polyols | MRPL21, RER1, PCBP1 | PDE2A 4844/4885KIF11 1941/4885HDAC3 3659/4885 |
| US-20100010093-A1 | ANTIPARASITIC AGENTS | HRH3, CYTH3, HRH4 | PDE2A 1893/4885KIF11 2138/4885HDAC3 89/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | PDE2A 1289/4885KIF11 2748/4885HDAC3 1235/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | PDE2A 2161/4885KIF11 4868/4885HDAC3 4321/4885 |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | PDE2A 890/4885KIF11 2888/4885HDAC3 1113/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PDE2A 2161/4885KIF11 4868/4885HDAC3 4321/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | PDE2A 1862/4885KIF11 1995/4885HDAC3 468/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PDE2A 2161/4885KIF11 4868/4885HDAC3 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.